{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T23:20:39Z","timestamp":1648596039627},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.1016\/j.ygyno.2004.07.017","type":"journal-article","created":{"date-parts":[[2004,9,8]],"date-time":"2004-09-08T14:32:55Z","timestamp":1094653975000},"page":"109-113","source":"Crossref","is-referenced-by-count":8,"title":["Phase 2 trial of prolonged administration of oral topotecan in platinum\/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers"],"prefix":"10.1016","volume":"95","author":[{"given":"Maurie","family":"Markman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Webster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine","family":"Zanotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Kulp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gertrude","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Belinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2004.07.017_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2004.07.017_bib2","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.07.017_bib3","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0889-8588(03)00058-3","article-title":"Optimizing primary chemotherapy in ovarian cancer","volume":"17","author":"Markman","year":"2003","journal-title":"Hematol.\/Oncol. Clin. N. Am."},{"key":"10.1016\/j.ygyno.2004.07.017_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1634\/theoncologist.5-1-26","article-title":"Second-line treatment of ovarian cancer","volume":"5","author":"Markman","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2004.07.017_bib5","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.1996.14.12.3056","article-title":"Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study","volume":"14","author":"Creemers","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.07.017_bib6","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1200\/JCO.1998.16.10.3345","article-title":"Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel","volume":"16","author":"Bookman","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.07.017_bib7","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.2000.18.5.1062","article-title":"Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study","volume":"18","author":"McGuire","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.07.017_bib8","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"ten Bokkel Huinink","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.07.017_bib9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00685553","article-title":"Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors","volume":"31","author":"Houghton","year":"1992","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2004.07.017_bib10","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/oxfordjournals.annonc.a058623","article-title":"Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor","volume":"4","author":"Verweij","year":"1993","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2004.07.017_bib11","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/cncr.11690","article-title":"Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma. A Gynecologic Oncology Group study","volume":"98","author":"Miller","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2004.07.017_bib12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1006\/gyno.2000.5755","article-title":"Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study","volume":"77","author":"Markman","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.07.017_bib13","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.1998.16.6.2233","article-title":"Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study","volume":"16","author":"Hoskins","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.07.017_bib14","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1200\/JCO.1999.17.8.2553","article-title":"Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy","volume":"17","author":"Hochster","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.07.017_bib15","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0959-8049(97)10173-3","article-title":"Five days of oral topotecan (Hycamtin\u00ae), a phase I and pharmacological study in adult patients with solid tumours","volume":"34","author":"Gerrits","year":"1998","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2004.07.017_bib16","first-page":"69","article-title":"A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)","volume":"5","author":"Gerrits","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2004.07.017_bib17","first-page":"2685","article-title":"Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens","volume":"6","author":"Loos","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2004.07.017_bib18","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1200\/JCO.2001.19.19.3967","article-title":"Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer","volume":"19","author":"Clarke-Pearson","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.07.017_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0959-8049(01)00188-5","article-title":"A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer","volume":"38","author":"Gore","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2004.07.017_bib20","first-page":"868","article-title":"Phase II study of oral topotecan in advanced non-small cell lung cancer","volume":"6","author":"White","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2004.07.017_bib21","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1200\/JCO.2001.19.6.1743","article-title":"Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer","volume":"19","author":"Von Pawel","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.07.017_bib22","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1200\/JCO.1997.15.3.1087","article-title":"Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors","volume":"15","author":"Creemers","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.07.017_bib23","first-page":"199a","article-title":"A phase I study or oral topotecan in patients with refractory and\/or advanced malignancies","volume":"19","author":"Jones","year":"2000","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.07.017_bib24","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1200\/JCO.1994.12.3.553","article-title":"Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen","volume":"12","author":"Hochster","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.07.017_bib25","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.1996.14.9.2540","article-title":"Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer","volume":"14","author":"Creemers","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.07.017_bib26","first-page":"1245","article-title":"Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study","volume":"3","author":"Hochster","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2004.07.017_bib27","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.1999.17.2.501","article-title":"Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel","volume":"17","author":"Bridgewater","year":"1999","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825804005359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825804005359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T03:20:50Z","timestamp":1549250450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825804005359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["S0090825804005359"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2004.07.017","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2004,10]]}}}